Covalent PROTACs: the best of both worlds?
Year: 2021
Type: article
Abstract: Covalent PROTACs combine the cutting edge research areas of targeted covalent inhibitors (TCIs) and proteolysis targeting chimeras (PROTACs). This nascent field of research has already demonstrated several interesting findings, and holds an immense amount of potential to expand the druggable proteome. In this opinion, we present some of these intriguing early findings and discuss the potential advantages and disadvantages of this approach.
Source: RSC Medicinal Chemistry
DOI: 10.1039/d1md00191d
Author: Neil P. Grimster
Institution: AstraZeneca (United States)
Language: English
Subfield: Molecular Biology
Domain: Life Sciences
Open Access status: green
OpenAlex ID: W3193761646
